FDA OTC Ophthalmic Drug Products — Eye Drop Monograph Standards

Walk into any pharmacy and you'll find dozens of eye drop products — artificial tears, redness relievers, antihistamine drops, dry eye treatments. How does any of these products end up on that shelf without a prescription? The answer is the FDA's OTC Drug Review — a system established in 1972 that evaluates whether specific active ingredients in over-the-counter drugs are "generally recognized as safe and effective" (GRASE). For eye drops, 21 CFR Part 349 is the final outcome of that review: a monograph specifying which active ingredients may be sold in non-prescription ophthalmic products, at what concentrations, in what combinations, and with what labeling. A product formulated within Part 349's specifications may be marketed without a New Drug Application — the monograph is a standing authorization.

Legal Authority

• 21 U.S.C. § 355 — FDCA § 505: OTC ophthalmic products are drugs; compliance with 21 CFR Part 349 (the ophthalmic monograph) provides the regulatory basis for marketing without an individual NDA
• 21 U.S.C. § 321 — FDCA definitions: eye drop products formulated with active drug ingredients (vasoconstrictors, antihistamines, demulcents) are drugs, not cosmetics
• 21 CFR Part 349 — FDA OTC ophthalmic drug products monograph; specifies GRASE active ingredients for ophthalmic use, permitted concentrations, labeling requirements, and approved indications (redness relief, dry eye, eye wash)

Key Mechanics

Part 349 covers two primary categories of OTC eye drops: demulcent (dry eye) products and vasoconstrictor (redness relief) products. Demulcents are lubricating agents (polyvinyl alcohol, povidone, cellulose derivatives) that coat the ocular surface — their GRASE status requires specific concentrations and combinations. Vasoconstrictors (naphazoline, tetrahydrozoline, oxymetazoline) work by constricting dilated blood vessels to reduce redness; their GRASE status comes with warnings about rebound redness with overuse. OTC antihistamine eye drops (ketotifen) have a different regulatory pathway — they were approved through an NDA, not monograph. Ophthalmic products have strict sterility requirements (21 CFR § 200.50): they must be sterile because the eye is vulnerable to infection; this requirement applies regardless of GRASE status.

Current Rule (2026)

What This Rule Does

The FDA's OTC Drug Review, launched by the Nixon administration in 1972, was one of the largest regulatory undertakings in FDA history: systematic review of the thousands of OTC drug products on the market to determine whether their active ingredients were safe and effective. For ophthalmic (eye) drugs, the review produced what is now codified at Part 349 — a final monograph specifying the categories of active ingredients permitted in nonprescription eye drops and their conditions of use.

A manufacturer who wants to sell an OTC eye drop product has two pathways: (1) formulate the product in full compliance with Part 349's monograph (conforming active ingredient, concentration within the specified range, labeled indications matching the monograph, and compliant labeling); or (2) file a New Drug Application (NDA) for a novel active ingredient or formulation not covered by the monograph. The monograph pathway avoids the time and expense of an NDA for products using established ingredients; the NDA pathway is required for innovation beyond the monograph's boundaries (for example, cyclosporine ophthalmic emulsion, sold as Restasis, is a prescription NDA product not covered by Part 349).

The CARES Act of 2020 fundamentally changed how FDA updates OTC monographs. Before CARES, updating a monograph required going through notice-and-comment rulemaking, which could take years or decades. After CARES, FDA can amend OTC monographs through administrative orders — a faster, more flexible process. Part 349's current text reflects both the original rulemaking and subsequent administrative order updates.

Key Provisions

• § 349.3 — Definitions: "ophthalmic drug product" — a drug product in a form suitable for topical application to the eye, which should be sterile in accordance with FDA sterility standards; the sterility requirement for ophthalmic products is absolute — a non-sterile eye drop is adulterated per se, regardless of whether it contains a listed active ingredient in the correct concentration; "astringent" — an agent that causes contraction of tissues; "demulcent" — a soothing substance that protects irritated, inflamed, or abraded surfaces

• § 349.10 — Ophthalmic astringents: the only permitted OTC astringent is zinc sulfate, at a concentration of 0.25%; zinc sulfate causes minor tissue contraction and mild astringent effect; products using zinc sulfate must be labeled as "ophthalmic astringent" or "eye drops"; the narrow permitted concentration range (exactly 0.25%) means there is no flexibility for manufacturers — a product with 0.30% zinc sulfate falls outside the monograph

• § 349.12 — Ophthalmic demulcents: the largest category — these are the lubricating and moisture-retaining agents that form the basis of artificial tear products; permitted demulcents include:

  • Carboxymethylcellulose sodium (0.2–2.5%)
  • Dextran 70 (0.1%)
  • Gelatin (0.01%)
  • Glycerin (0.2–1%)
  • Hypromellose (hydroxypropyl methylcellulose, 0.2–2.5%)
  • Methylcellulose (0.2–2.5%)
  • Polyethylene glycol 300 or 400 (0.2–1%)
  • Polysorbate 80 (0.2%)
  • Polyvinyl alcohol (0.1–4%)
  • Povidone (0.1–2%)
  • Propylene glycol (0.2–1%)
  • Dextran 70 (0.1%) — can be combined with hypromellose in a permitted combination under § 349.30

• § 349.14 — Ophthalmic emollients: lanolin preparations and white petrolatum; emollients protect the ocular surface by forming a lipid layer that reduces evaporative water loss; used in lubricating ointments (as opposed to drops) for nighttime dry eye treatment; white petrolatum is permitted at 30–100% in ointments; these thick formulations blur vision transiently and are typically recommended for bedtime use only

• § 349.16 — Ophthalmic hypertonicity agent: sodium chloride at 2–5% (hypertonic saline solution); used for the temporary relief of corneal edema (swelling of the cornea, sometimes occurring in bullous keratopathy or after sleeping with contact lenses); hypertonic saline draws fluid from the edematous cornea by osmosis; marketed as products like Muro 128; the high concentration (above the normal 0.9% physiological saline) distinguishes this from simple saline rinses

• § 349.18 — Ophthalmic vasoconstrictors: the "redness reliever" active ingredients — these constrict conjunctival blood vessels, reducing the appearance of red eyes:

  • Naphazoline hydrochloride (0.01–0.1%)
  • Phenylephrine hydrochloride (0.08–0.2%)
  • Tetrahydrozoline hydrochloride (0.01–0.05%)
  • These are alpha-adrenergic agonists; the "rebound redness" phenomenon (persistent or worsening redness with overuse) is a well-recognized consequence of regular vasoconstrictor use; FDA's labeling requirements for vasoconstrictors must include directions to discontinue use if redness continues for more than 72 hours and to avoid use in patients with narrow-angle glaucoma

• § 349.20 — Eyewashes: active ingredient is purified water; eyewashes are designed to flush foreign bodies and irritants from the eye; must contain suitable tonicity agents (typically sodium chloride at physiological concentration); marketed as eyewash stations in industrial settings and in personal eyewash kits; the product must be sterile and isotonic

• § 349.30 — Permitted combinations: certain combinations of ingredients from different active categories are specifically permitted; notable combinations include dextran 70 with hypromellose (the formulation basis of certain artificial tear products); and demulcents with vasoconstrictors (artificial tear products with redness relief); combinations not specifically listed in § 349.30 require an NDA or an administrative order amending the monograph

• §§ 349.50–349.78 — Labeling requirements by category: each product category has specific labeling requirements — statement of identity, indications, warnings, and directions; the vasoconstrictor labeling must include a warning to discontinue if redness persists more than 72 hours; demulcent labeling must indicate the product is for "temporary relief of burning and irritation due to dryness of the eye"; all ophthalmic drug products must include instructions to discard if solution changes color or becomes cloudy; contact lens compatibility labeling is required where applicable

How It Affects You

If you sell OTC eye drop products: Part 349 defines the universe of products you can market without an NDA. Formulate within the monograph (listed active ingredients, listed concentrations, conforming labeling), and you can market without individual FDA approval. Deviate from the monograph — a new active ingredient, a concentration outside the listed range, a combination not specifically permitted — and you need an NDA or an administrative order amendment. The sterility requirement is non-negotiable: a failure of sterility in ophthalmic manufacturing is a Class I recall situation (reasonable probability of serious adverse health consequences); FDA has issued numerous enforcement letters and consent decrees against ophthalmic manufacturers for sterility failures at manufacturing facilities.

If you are an eye care professional or patient using OTC eye drops: demulcent products (artificial tears) are the most widely used eye drops in the U.S. — approximately 100 million units sold annually — and are generally considered safe for frequent use. Vasoconstrictor products (redness relievers) warrant caution with regular use: the rebound redness phenomenon and the contraindication in narrow-angle glaucoma (where vasoconstriction can trigger acute angle-closure crisis) are clinically significant. Products marketed for "dry eye disease" using prescription active ingredients (cyclosporine A, lifitegrast) are not OTC monograph products — they require prescriptions and are not covered by Part 349.

If you manufacture ophthalmic products: FDA's Current Good Manufacturing Practice (cGMP) requirements for ophthalmic drug products (21 CFR Part 211, Subpart D) are among the most demanding in pharmaceutical manufacturing. Environmental monitoring programs for sterile fill areas, laminar flow hood qualification, container closure integrity testing, and endotoxin testing requirements all apply to monograph ophthalmic products. FDA routinely inspects ophthalmic manufacturing facilities as part of its drug manufacturing surveillance; import alerts have been issued against multiple foreign manufacturers of ophthalmic products for cGMP deficiencies.

Statutory Authority

This rule implements:

• 21 U.S.C. § 355 — FDCA § 505, the new drug approval requirement; the OTC monograph system creates a regulatory safe harbor from the § 505 NDA requirement for products conforming to the monograph
• 21 U.S.C. § 321(p) — FDCA § 201(p), definition of "new drug" — a product whose safety and effectiveness is not generally recognized by qualified experts; the OTC review process establishes which active ingredients are GRASE and therefore not "new drugs" requiring individual approval
• 21 U.S.C. § 355h — OTC Drug Review reform authority added by CARES Act of 2020; authorizes FDA to use administrative orders rather than notice-and-comment rulemaking to update OTC monographs

Recent Rulemakings

• 86 FR 52637 (September 2021) — administrative order under CARES Act; minor conforming update to Part 349 to reflect the new administrative order mechanism for OTC monograph updates
• 82 FR 35312 (July 2017) — proposed amendment to address the decongestant and redness reliever classification of naphazoline; final not yet issued as of 2024
• Original final monograph: 53 FR 12672 (April 15, 1988) — finalization of the ophthalmic OTC monograph following years of OTC Drug Review deliberation; established the fundamental framework of permitted categories and ingredients that remains in place today

Pending Action